UNSPSC 51182079: Trenbolone cyclohexylmethylcarbonate

This classification denotes an anabolic steroid with the molecular formula C26H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BNJ7Y3JFF2, chemically known as estra-4,9,11-trien-3-one, 17-(((cyclohexylmethoxy)carbonyl)oxy)-, (17.beta.)-, but more generally known as trenbolone cyclohexylmethylcarbonate, which bears US NIH Compound Identifier 90930. European Medicines Agency schedules trenbolone cyclohexylmethylcarbonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11232MIG.

Most nations, for tariff purposes, schedule trenbolone cyclohexylmethylcarbonate under HS 29372900. SMILES: C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC5CCCCC5.

UNSPSC 51182079 Trenbolone cyclohexylmethylcarbonate is a Commodity code that covers a specific pharmaceutical active ingredient, but the recent state and local procurement activity tagged under it reflects broader generic multi-source pharmaceutical and over-the-counter product supply agreements rather than this single compound. State and local governments use codes in this family to procure pharmaceuticals for distribution through health departments, correctional facilities, public hospitals, and other government-operated medical services. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities. Issuing bodies under pharmaceutical codes include state health departments, departments of corrections, state purchasing offices managing cooperative agreements, and occasionally individual county health systems; MMCAP serves as a multi-state vehicle pooling demand across member states including Oregon and Minnesota.

The MMCAP RFP, due March 26, 2026, requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—with pricing evaluated at 75 percent weight and administrative compliance at 25 percent combined. Vendors must maintain contractual relationships with at least two of the three wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, carry insurance including $5 million commercial general liability and $2 million network security and privacy liability, and accept a 3 percent administrative fee on all purchases. Products must be available by May 15, 2026, with contracts effective July 1, 2026 for two-year terms with optional extensions. The procurement spans Minnesota and Oregon, with broader multistate participation expected through MMCAP's cooperative model. No award ceiling is disclosed; the RFP does not identify set-aside restrictions for disadvantaged enterprises based on available documentation.